sustained-release anagrelide (Revitus)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namesustained-release anagrelide (Revitus)
Drug Alias NameRevidin
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action3',5'-cyclic phosphodiesterase inhibitorsPhosphodiesterase 3 inhibitorsCoagulation factor inhibitors
TargetsPhosphodiesterase 3Coagulation factor3',5'-cyclic phosphodiesterase
Therapy Area/IndicationsArteriosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRevitus
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRevitus
Active IndicationsN/A
Inactive IndicationsArteriosclerosis

Other Information

ATC CodeN/A
Related LinksN/A